Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy.

Kasteleijn-Nolst Trenité DG, Biton V, French JA, Abou-Khalil B, Rosenfeld WE, Diventura B, Moore EL, Hetherington SV, Rigdon GC.

Epilepsia. 2013 Aug;54(8):1437-43. doi: 10.1111/epi.12224. Epub 2013 May 20.

2.

Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.

Minniti CP, Wilson J, Mendelsohn L, Rigdon GC, Stocker JW, Remaley AT, Kato GJ.

Br J Haematol. 2011 Dec;155(5):634-6. doi: 10.1111/j.1365-2141.2011.08757.x. Epub 2011 Jun 8. No abstract available.

3.

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Amato G, Roeloffs R, Rigdon GC, Antonio B, Mersch T, McNaughton-Smith G, Wickenden AD, Fritch P, Suto MJ.

ACS Med Chem Lett. 2011 Mar 31;2(6):481-4. doi: 10.1021/ml200053x. eCollection 2011 Jun 9.

4.

In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.

Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J, McNamara JO, Ghodadra N, Rigdon GC.

J Pharmacol Exp Ther. 2008 Sep;326(3):818-28. doi: 10.1124/jpet.108.137794. Epub 2008 Jun 24.

PMID:
18577704
5.

Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.

McNaughton-Smith GA, Burns JF, Stocker JW, Rigdon GC, Creech C, Arrington S, Shelton T, de Franceschi L.

J Med Chem. 2008 Feb 28;51(4):976-82. doi: 10.1021/jm070663s. Epub 2008 Jan 31.

PMID:
18232633
6.

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators.

Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11.

7.

N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, Roeloffs R, McNaughton-Smith G, Rigdon GC.

Mol Pharmacol. 2008 Mar;73(3):977-86. Epub 2007 Dec 18.

PMID:
18089837
8.
9.

Indanylidenes. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent, centrally acting muscle relaxant with antiinflammatory and analgesic activity.

Musso DL, Cochran FR, Kelley JL, McLean EW, Selph JL, Rigdon GC, Orr GF, Davis RG, Cooper BR, Styles VL, Thompson JB, Hall WR.

J Med Chem. 2003 Jan 30;46(3):399-408.

PMID:
12540239
10.

Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents.

Norman MH, Navas F 3rd, Thompson JB, Rigdon GC.

J Med Chem. 1996 Nov 22;39(24):4692-703.

PMID:
8941382
11.

1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects.

Rigdon GC, Norman MH, Cooper BR, Howard JL, Boncek VM, Faison WL, Nanry KP, Pollard GT.

Neuropsychopharmacology. 1996 Sep;15(3):231-42.

12.
13.
14.

Is clozapine selective for the dopamine D4 receptor?

Durcan MJ, Rigdon GC, Norman MH, Morgan PF.

Life Sci. 1995;57(18):PL275-83.

PMID:
7475902
15.

Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.

Norman MH, Rigdon GC, Navas F 3rd, Cooper BR.

J Med Chem. 1994 Aug 5;37(16):2552-63.

PMID:
7914539
16.

A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.

Chang KJ, Rigdon GC, Howard JL, McNutt RW.

J Pharmacol Exp Ther. 1993 Nov;267(2):852-7.

PMID:
8246159
17.

5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.

Rigdon GC, Weatherspoon JK.

J Pharmacol Exp Ther. 1992 Nov;263(2):486-93.

PMID:
1432685
18.
19.

Effect of perinatal monosodium glutamate administration on visual evoked potentials of juvenile and adult rats.

Rigdon GC, Boyes WK, Dyer RS.

Neurotoxicol Teratol. 1989 Mar-Apr;11(2):121-8.

PMID:
2733651
20.

Ketamine alters rat flash evoked potentials.

Rigdon GC, Dyer RS.

Pharmacol Biochem Behav. 1988 Jun;30(2):421-6.

PMID:
3174774
21.

Ontogeny of flash-evoked potentials in unanesthetized rats.

Rigdon GC, Dyer RS.

Int J Dev Neurosci. 1987;5(5-6):447-54.

PMID:
3503515
22.

Urethane affects the rat visual system at subanesthetic doses.

Dyer RS, Rigdon GC.

Physiol Behav. 1987;41(4):327-30.

PMID:
3432386
23.
24.

Generation of cortical event-related slow potentials in the rat involves nucleus basalis cholinergic innervation.

Pirch JH, Corbus MJ, Rigdon GC, Lyness WH.

Electroencephalogr Clin Neurophysiol. 1986 May;63(5):464-75.

PMID:
2420562
25.

Conditioning-related single unit activity in the frontal cortex of urethane anesthetized rats.

Pirch JH, Corbus MJ, Rigdon GC.

Int J Neurosci. 1985 Jan;25(3-4):263-71.

PMID:
3872287
27.

Single-unit and slow potential responses from rat frontal cortex during associative conditioning.

Pirch JH, Corbus MJ, Rigdon GC.

Exp Neurol. 1983 Oct;82(1):118-30.

PMID:
6605259
28.

Dissimilar responses of cortical neurons to chronic trazodone or desipramine treatment.

Peterson SL, Napier TC, Rigdon GC, Pirch JH.

Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(2-3):175-81.

PMID:
6310689

Supplemental Content

Loading ...
Support Center